GENERAL COMMENTS
This protocol addresses the question of the safety and feasibility of TXA administration of a pilot study in preparation for a larger trial. While safety may be the most important objective, the pilot study is powered for 'feasibility' i.e., can the researchers successfully administer TXA or placebo to 85% of the patients recruited. Under the sample size, it would be helpful to have more detail on what power will be available to address the safety issues (and what is defined as 'safe' in the context of this study).
Other minor comments: Under the cost analyses section, please clarify if the costs given are in USD (2017)? I think it's important to clarify as TXA costs may change. Thus, the literature support the use of tranexamic acid in vaginal deliveries, caesareans, and hysterectomies and do reduce blood transfusions, peripartum haemorhage, postoperative complications/ re-operations. However, the studies are of mixed quality, with insufficient evidence about the potential side effects. This also means that any generalizability might be difficult. This pilot study prior to a large scale study, might provide the missing evidence. They seem to have all the right statements and approvals, addressing inclusions and exclusions, the randomization process, the blinding, and the ethical issues. I Will be looking forward to see their results.
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GENERAL COMMENTS
Thanks for the nice protocol prepared for this important study
VERSION 1 -AUTHOR RESPONSE
Reviewer: Elizabeth McClure
Comment: Under the sample size, it would be helpful to have more detail on what power will be available to address the safety issues (and what is defined as 'safe' in the context of this study).
Response: We have now included this in the manuscript.
Comment: Under the cost analyses section, please clarify if the costs given are in USD (2017)? I think it's important to clarify as TXA costs may change.
